| Symbol | CNTX |
|---|---|
| Name | CONTEXT THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2001 MARKET STREET, UNIT NO 15,SUITE 3915, PHILADELPHIA, Pennsylvania, 19103, United States |
| Telephone | +1 267 225-7416 |
| Fax | — |
| — | |
| Website | https://www.contexttherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001842952 |
| Description | Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics with multiple products in development, including two clinical-stage assets. Context is headquartered in Philadelphia. Additional info from NASDAQ: |
2026-07-31 17:02
New Form SCHEDULE 13G/A - Context Therapeutics Inc. <b>Filed:</b> 2026-07-31 <b>AccNo:</b> 0001214659-26-009404 <b>Size:</b> 11 KB
Read more
2026-06-15 13:18
(10% Negative) CONTEXT THERAPEUTICS INC. (CNTX) Announces Clinical Trial Timeline Adjustment
Read more
2026-06-15 10:30
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
Read more
2026-06-09 20:10
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Read more
2026-05-27 11:30
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
Read more
2026-05-18 10:47
(85% Positive) CONTEXT THERAPEUTICS INC. (CNTX) Announces Enrollment Update for antibodies Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read more
2026-05-18 10:45
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
Read more
2026-05-15 09:55
New Form SCHEDULE 13G/A - Context Therapeutics Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001172661-26-002036 <b>Size:</b> 11 KB
Read more
2026-05-14 17:20
New Form SCHEDULE 13G/A - Context Therapeutics Inc. <b>Filed:</b> 2026-05-14 <b>AccNo:</b> 0001140361-26-021316 <b>Size:</b> 7 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07545122 | A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispeci… | Phase1 | Triple Negative Breast Cancer (TNBC) | Not_Yet_Recruiting | 2026-09-01 | 2030-01-01 | ClinicalTrials.gov |
| NCT07270601 | Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis | Na | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | Recruiting | 2025-11-17 | 2026-12-31 | ClinicalTrials.gov |
| NCT07686874 | SCIENCE DES ÉMOTIONS : Evaluation of a Psychosocial Skills Development Program … | Na | Feasibility Studies - Efficacy of Intervention Psychosocial Skills Learning | Active_Not_Recruiting | 2025-07-01 | 2027-12-20 | ClinicalTrials.gov |
| NCT06756035 | CT-95 in Advanced Cancers Associated With Mesothelin Expression | Phase1 | Mesothelin-Expressing Tumors | Recruiting | 2025-03-31 | 2028-12-01 | ClinicalTrials.gov |
| NCT06515613 | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other … | Phase1 | Platinum-resistant Ovarian Cancer | Recruiting | 2024-07-10 | 2028-12-31 | ClinicalTrials.gov |
| NCT05885984 | Acceptance and Commitment Therapy on Fatigue Interference in Patients With Adva… | Na | Lung Cancer | Unknown | 2023-07-01 | 2024-01-01 | ClinicalTrials.gov |
| NCT06938711 | A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patien… | Phase1 | Breast Cancer | Withdrawn | 2023-06-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT05618613 | Study of Elacestrant in Combination With Onapristone in Patients With Advanced … | Phase1 | Breast Cancer | Terminated | 2022-12-02 | 2023-06-23 | ClinicalTrials.gov |
| NCT05481762 | Evaluation of Contextflow DETECT Lung CT Nodule Detection Software in Chest CT … | — | Lung Cancer | Completed | 2022-04-01 | 2022-10-30 | ClinicalTrials.gov |
| NCT04738292 | Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocr… | Phase2 | ER-positive Breast Cancer | Terminated | 2021-10-05 | 2023-05-15 | ClinicalTrials.gov |
| NCT04872608 | A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic… | Phase1 | Metastatic Breast Cancer | Withdrawn | 2021-09-09 | 2023-04-25 | ClinicalTrials.gov |
| NCT04719273 | Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Po… | Phase2 | Refractory Endometrial Adenocarcinoma | Completed | 2021-01-28 | 2025-12-17 | ClinicalTrials.gov |
| NCT03909152 | A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecolog… | Phase2 | Granulosa Cell Ovarian Cancer | Completed | 2019-05-02 | 2024-09-03 | ClinicalTrials.gov |
| NCT02761681 | Mindfulness and Acceptance Applied in Colleges Through Web-Based Guided Self-He… | Na | Mental Health | Completed | 2015-04-01 | 2019-06-01 | ClinicalTrials.gov |
| NCT01808404 | Mindfulness and Acceptance Applied in Colleges Through Web-Based Guided Self-He… | Phase1 | College Student Mental Health | Completed | 2013-02-01 | 2013-09-01 | ClinicalTrials.gov |
Total clinical trials: 15
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Onapristone | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05618613 |
| Elacestrant | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05618613 |
| Progesterone Receptor Positive ( PGR Positive; PR Positive) | Other | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | COMPLETED | NCT04719273 |
| Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive) | Other | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | COMPLETED | NCT04719273 |
| Questionnaire Administration | Other | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | COMPLETED | NCT04719273 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | COMPLETED | NCT04719273 |
| Anastrozole | Other | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | COMPLETED | NCT04719273 |
| Extended-release Onapristone | Other | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | COMPLETED | NCT04719273 |
| CT-202 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07545122 |
| Socio-emotional curriculum - Science des Emotions | Other | Approved | Feasibility Studies - Efficacy of Intervention Psychosocial Skills Learning | ACTIVE_NOT_RECRUITING | NCT07686874 |
| CTIM-76 | Other | Phase PHASE1 | Platinum-resistant Ovarian Cancer | RECRUITING | NCT06515613 |
| CT-95 | Other | Phase PHASE1 | Mesothelin-Expressing Tumors | RECRUITING | NCT06756035 |
| CT-95 | Other | Phase PHASE1 | Mesothelin-Expressing Tumors | RECRUITING | NCT06756035 |
| CTIM-76 | Other | Phase PHASE1 | Platinum-resistant Ovarian Cancer | RECRUITING | NCT06515613 |
| Web-Based Guided Self-Help | Other | Phase PHASE1 | College Student Mental Health | COMPLETED | NCT01808404 |
| Web-Based Guided Self-Help | Other | Phase PHASE1 | College Student Mental Health | COMPLETED | NCT01808404 |
| Control Web-based guided self-help | Other | Approved | Mental Health | COMPLETED | NCT02761681 |
| ACT-CL Web-based guided self-help | Other | Approved | Mental Health | COMPLETED | NCT02761681 |
| Control Web-based guided self-help | Other | Approved | Mental Health | COMPLETED | NCT02761681 |
| ACT-CL Web-based guided self-help | Other | Approved | Mental Health | COMPLETED | NCT02761681 |
| Aided read with contextflow DETECT Lung CT | Other | Preclinical | Lung Cancer | COMPLETED | NCT05481762 |
| Aided read with contextflow DETECT Lung CT | Other | Preclinical | Lung Cancer | COMPLETED | NCT05481762 |
| Onapristone ER | Other | Phase PHASE1 | Metastatic Breast Cancer | WITHDRAWN | NCT04872608 |
| Palbociclib | Other | Phase PHASE1 | Metastatic Breast Cancer | WITHDRAWN | NCT04872608 |
| Letrozole | Other | Phase PHASE1 | Metastatic Breast Cancer | WITHDRAWN | NCT04872608 |
| Health education | Other | Approved | Lung Cancer | UNKNOWN | NCT05885984 |
| Acceptance and Commitment Therapy (ACT) plus health education | Drug | Approved | Lung Cancer | UNKNOWN | NCT05885984 |
| Health education | Other | Approved | Lung Cancer | UNKNOWN | NCT05885984 |
| Acceptance and Commitment Therapy (ACT) plus health education | Drug | Approved | Lung Cancer | UNKNOWN | NCT05885984 |
| Health education | Other | Approved | Lung Cancer | UNKNOWN | NCT05885984 |
| Acceptance and Commitment Therapy (ACT) plus health education | Drug | Approved | Lung Cancer | UNKNOWN | NCT05885984 |
| Fulvestrant | Other | Phase PHASE2 | ER-positive Breast Cancer | TERMINATED | NCT04738292 |
| Onapristone | Other | Phase PHASE2 | ER-positive Breast Cancer | TERMINATED | NCT04738292 |
| Progesterone Receptor Positive ( PGR Positive; PR Positive) | Other | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive) | Other | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Questionnaire Administration | Other | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Quality-of-Life Assessment | Other | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Anastrozole | Other | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Extended-release Onapristone | Other | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Onapristone | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT06938711 |
| Elacestrant | Other | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT06938711 |
| Onapristone | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05618613 |
| Elacestrant | Other | Phase PHASE1 | Breast Cancer | TERMINATED | NCT05618613 |
| Onapristone ER + Anastrozole | Other | Phase PHASE2 | Granulosa Cell Ovarian Cancer | COMPLETED | NCT03909152 |
| Onapristone ER | Other | Phase PHASE2 | Granulosa Cell Ovarian Cancer | COMPLETED | NCT03909152 |
| CT-95 | Other | Phase PHASE1 | Mesothelin-Expressing Tumors | RECRUITING | NCT06756035 |
| Philips 3T Ingenia Elition | Other | Approved | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT07270601 |
| EchoSense FibroScan | Other | Approved | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT07270601 |
| Philips EPIQ Elite | Other | Approved | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT07270601 |
| Verasonics NXT Data Acquisition System | Other | Approved | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT07270601 |
| Philips 3T Ingenia Elition | Other | Approved | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT07270601 |
| EchoSense FibroScan | Other | Approved | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT07270601 |
| Philips EPIQ Elite | Other | Approved | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT07270601 |
| Verasonics NXT Data Acquisition System | Other | Approved | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | RECRUITING | NCT07270601 |
| CTIM-76 | Other | Phase PHASE1 | Platinum-resistant Ovarian Cancer | RECRUITING | NCT06515613 |
| CT-202 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07545122 |
| CT-202 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07545122 |
| CT-202 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07545122 |
| CT-202 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07545122 |
| CT-202 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07545122 |
| CT-202 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07545122 |
| CT-202 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07545122 |
| CT-202 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07545122 |
| CT-95 | DRUG | Phase PHASE1 | Mesothelin-Expressing Tumors | RECRUITING | NCT06756035 |
| CTIM-76 | DRUG | Phase PHASE1 | Platinum-resistant Ovarian Cancer | RECRUITING | NCT06515613 |
| Elacestrant | DRUG | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT06938711 |
| Palbociclib | DRUG | Phase PHASE1 | Metastatic Breast Cancer | WITHDRAWN | NCT04872608 |
| Letrozole | DRUG | Phase PHASE1 | Metastatic Breast Cancer | WITHDRAWN | NCT04872608 |
| Fulvestrant | DRUG | Phase PHASE2 | ER-positive Breast Cancer | TERMINATED | NCT04738292 |
| Onapristone | DRUG | Phase PHASE1 | Breast Cancer | WITHDRAWN | NCT06938711 |
| Questionnaire Administration | OTHER | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Quality-of-Life Assessment | OTHER | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Anastrozole | DRUG | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Extended-release Onapristone | DRUG | Phase PHASE2 | Refractory Endometrial Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04719273 |
| Onapristone ER + Anastrozole | DRUG | Phase PHASE2 | Granulosa Cell Ovarian Cancer | COMPLETED | NCT03909152 |
| Onapristone ER | DRUG | Phase PHASE1 | Metastatic Breast Cancer | WITHDRAWN | NCT04872608 |
Total products: 76